2,785 research outputs found
EV charging stations and RES-based DG: A centralized approach for smart integration in active distribution grids
Renewable Energy Sources based (RES-based) Dispersed Generation (DG) and Electrical Vehicles (EVs) charging systems diffusion is in progress in many Countries around the word. They have huge effects on the distribution grids planning and operation, particularly on MV and LV distribution grids. Many studies on their impact on the power systems are ongoing, proposing different approaches of managing. The present work deals with a real application case of integration of EVs charging stations with ES-based DG. The final task of the integration is to be able to assure the maximum utilization of the distribution grid to which both are connected, without any upgrading action, and in accordance with Distribution System Operators (DSOs) needs. The application of the proposed approach is related to an existent distribution system, owned by edistribuzione, the leading DSO in Italy. Diverse types of EVs supplying stations, with diverse diffusion scenarios, have been assumed for the case study; various Optimal Power Flow (OPF) models, based on diverse objective functions, reflecting DSO necessities, have been applied and tried. The obtained results demonstrate that a centralized management approach by the DSO, could assure the respect of operation limits of the system in the actual asset, delaying or avoiding upgrading engagements and charges
Strategies for improving the sustainability of data centers via energy mix, energy conservation, and circular energy
Information and communication technologies (ICT) are increasingly permeating our daily life and we ever more commit our data to the cloud. Events like the COVID-19 pandemic put an exceptional burden upon ICT. This involves increasing implementation and use of data centers, which increased energy use and environmental impact. The scope of this work is to summarize the present situation on data centers as to environmental impact and opportunities for improvement. First, we introduce the topic, presenting estimated energy use and emissions. Then, we review proposed strategies for energy efficiency and conservation in data centers. Energy uses pertain to power distribution, ICT, and non-ICT equipment (e.g., cooling). Existing and prospected strategies and initiatives in these sectors are identified. Among key elements are innovative cooling techniques, natural resources, automation, low-power electronics, and equipment with extended thermal limits. Research perspectives are identified and estimates of improvement opportunities are mentioned. Finally, we present an overview on existing metrics, regulatory framework, and bodies concerned
Studenti svantaggiati e fattori di promozione della resilienza
Molti studi evidenziano lâimpatto che il contesto socio-economico e diverse caratteristiche degli studenti, quali il genere e il background migratorio, hanno sul raggiungimento di adeguate competenze in matematica. Questa situazione pone un problema di equitĂ del
sistema educativo e formativo: alcuni gruppi di giovani sono infatti svantaggiati in partenza per motivi indipendenti dal loro impegno nello studio. Lâobiettivo del presente lavoro Ăš valutare la presenza di fattori, su cui Ăš possibile un intervento da parte degli insegnanti,
che consentano a studenti svantaggiati di raggiungere risultati di eccellenza. Il contributo mira a identificare fattori associati non solo a una compensazione dello svantaggio legato alle condizioni di sfondo degli studenti, ma a una vera e propria inversione delle previsioni
in termini di competenze raggiunte. I risultati mostrano lâimpatto che lâappartenenza geografica, il background socio-economico-culturale delle scuole e delle famiglie e il genere, nella loro interazione, esercitano nel definire situazioni di forte svantaggio di partenza per
gli studenti. Allo stesso tempo, gli esiti mettono in luce il ruolo protettivo giocato da alcune strategie dâinsegnamento, dalle convinzioni di autoefficacia degli studenti e da altri fattori legati a specifiche situazioni di contesto.Many studies showed the impact that the socio-economic context and studentsâ characteristics, such as gender and migratory background, have on mathematical performance. This situation poses a problem of equity of the educational system: some groups of young people are in fact disadvantaged for reasons independent of their commitment to the study. The aim of this paper is to evaluate the presence of factors on which teachers can intervene, allowing disadvantaged students to achieve excellence. The contribution aims to identify associated factors not only to compensate for the disadvantage associated with student background conditions, but to a real reversal of predictions in terms of skills acquired. The results show the impact that geographic membership, the socio-economic-cultural background of schools and families and gender, in their interaction, exert in defining situations of major disadvantage for students. At the same time, there is evidence for the protective role played by some teaching strategies, student self-beliefs, and other factors related to specific background situations
Realized extreme quantile: A joint model for conditional quantiles and measures of volatility with EVT refinements
We propose a new framework exploiting realized measures of volatility to estimate and forecast extreme quantiles. Our realized extreme quantile (REQ) combines quantile regression with extreme value theory and uses a measurement equation that relates the realized measure to the latent conditional quantile. Model estimation is performed by quasi maximum likelihood, and a simulation experiment validates this estimator in finite samples. An extensive empirical analysis shows that high-frequency measures are particularly informative of the dynamic quantiles. Finally, an out-of-sample forecast analysis of quantile-based risk measures confirms the merit of the REQ
Weekly chemotherapy in advanced prostatic cancer.
This randomised phase II study was performed in order to evaluate the effectiveness of a weekly chemotherapy regimen in advanced prostatic carcinoma patients (stage D2) refractory to hormonal therapy. Seventy-two cases were studied: they were randomised in a 2:1 ratio to receive either epirubicin (30 mg m-2 weekly) or doxorubicin (25 mg m-2 weekly); 48 patients received epirubicin and 24 received doxorubicin. After 12 courses of chemotherapy, the 45 evaluable patients in the epirubicin arm showed a response rate of 37.7% and the 21 evaluable patients in the doxorubicin arm showed a response rate of 33.3% (P = 0.51). Pain intensity, bone and prostatic tumour markers rapidly and significantly decreased in responders. An improvement in physical symptoms, functional conditions and in emotional well-being was observed in the majority of the treated patients. The histological analysis of bone metastases, performed before and after 12 courses of chemotherapy showed a significant reduction in neoplastic invasion and in new bone formation in responders. Cardiac performance worsened in five out of 45 patients and in ten out of 21 during the first 12 courses of epirubicin or doxorubicin respectively (P = 0.014). The median survival was 12.5 months in the epirubicin arm and 8.0 months in the doxorubicin arm (P = 0.042). Our data indicate that in advanced prostatic carcinoma, a weekly epirubicin regimen may give rapid palliative results, similar to that of doxorubicin, but with less side-effects
Pharmacological treatment for familial amyloid neuropathy
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess and compare the efficacy, acceptability, and tolerability of pharmacologic diseaseâmodifying agents for familial amyloid neuropathy (FAP)
Pharmacological treatment for familial amyloid polyneuropathy
Background:
Diseaseâmodifying pharmacological agents for transthyretin (TTR)ârelated familial amyloid polyneuropathy (FAP) have become available in the last decade, but evidence on their efficacy and safety is limited. This review focuses on diseaseâmodifying pharmacological treatment for TTRârelated and other FAPs, encompassing amyloid kinetic stabilisers, amyloid matrix solvents, and amyloid precursor inhibitors.
Objectives:
To assess and compare the efficacy, acceptability, and tolerability of diseaseâmodifying pharmacological agents for familial amyloid polyneuropathies (FAPs).
Search methods:
On 18 November 2019, we searched the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials, MEDLINE, and Embase. We reviewed reference lists of articles and textbooks on peripheral neuropathies. We also contacted experts in the field. We searched clinical trials registries and manufacturers' websites.
Selection criteria:
We included randomised clinical trials (RCTs) or quasiâRCTs investigating any diseaseâmodifying pharmacological agent in adults with FAPs.
Disability due to FAP progression was the primary outcome. Secondary outcomes were severity of peripheral neuropathy, change in modified body mass index (mBMI), quality of life, severity of depression, mortality, and adverse events during the trial.
Data collection and analysis:
We followed standard Cochrane methodology.
Main results:
The review included four RCTs involving 655 people with TTRâFAP. The manufacturers of the drugs under investigation funded three of the studies. The trials investigated different drugs versus placebo and we did not conduct a metaâanalysis.
One RCT compared tafamidis with placebo in earlyâstage TTRâFAP (128 randomised participants). The trial did not explore our predetermined disability outcome measures. After 18 months, tafamidis might reduce progression of peripheral neuropathy slightly more than placebo (Neuropathy Impairment Score (NIS) in the lower limbs; mean difference (MD) â3.21 points, 95% confidential interval (CI) â5.63 to â0.79; P = 0.009; lowâcertainty evidence). However, tafamidis might lead to little or no difference in the change of quality of life between groups (Norfolk Quality of LifeâDiabetic Neuropathy (Norfolk QOLâDN) total score; MD â4.50 points, 95% CI â11.27 to 2.27; P = 0.19; very lowâcertainty evidence). No clear betweenâgroup difference was found in the numbers of participants who died (risk ratio (RR) 0.65, 95% CI 0.11 to 3.74; P = 0.63; very lowâcertainty evidence), who dropped out due to adverse events (RR 1.29, 95% CI 0.30 to 5.54; P = 0.73; very lowâcertainty evidence), or who experienced at least one severe adverse event during the trial (RR 1.16, 95% CI 0.37 to 3.62; P = 0.79; very lowâcertainty evidence).
One RCT compared diflunisal with placebo (130 randomised participants). At month 24, diflunisal might reduce progression of disability (Kumamoto Score; MD â4.90 points, 95% CI â7.89 to â1.91; P = 0.002; lowâcertainty evidence) and peripheral neuropathy (NIS plus 7 nerve tests; MD â18.10 points, 95% CI â26.03 to â10.17; P < 0.001; lowâcertainty evidence) more than placebo. After 24 months, changes from baseline in the quality of life measured by the 36âItem ShortâForm Health Survey score showed no clear difference between groups for the physical component (MD 6.10 points, 95% CI 2.56 to 9.64; P = 0.001; very lowâcertainty evidence) and the mental component (MD 4.40 points, 95% CI â0.19 to 8.99; P = 0.063; very lowâcertainty evidence). There was no clear betweenâgroup difference in the number of people who died (RR 0.46, 95% CI 0.15 to 1.41; P = 0.17; very lowâcertainty evidence), in the number of dropouts due to adverse events (RR 2.06, 95% CI 0.39 to 10.87; P = 0.39; very lowâcertainty evidence), and in the number of people who experienced at least one severe adverse event (RR 0.77, 95% CI 0.18 to 3.32; P = 0.73; very lowâcertainty evidence) during the trial.
One RCT compared patisiran with placebo (225 randomised participants). After 18 months, patisiran reduced both progression of disability (Raschâbuilt Overall Disability Scale; leastâsquares MD 8.90 points, 95% CI 7.00 to 10.80; P < 0.001; moderateâcertainty evidence) and peripheral neuropathy (modified NIS plus 7 nerve tests â Alnylam version; leastâsquares MD â33.99 points, 95% CI â39.86 to â28.13; P < 0.001; moderateâcertainty evidence) more than placebo. At month 18, the change in quality of life between groups favoured patisiran (Norfolk QOLâDN total score; leastâsquares MD â21.10 points, 95% CI â27.20 to â15.00; P < 0.001; lowâcertainty evidence). There was little or no betweenâgroup difference in the number of participants who died (RR 0.61, 95% CI 0.21 to 1.74; P = 0.35; lowâcertainty evidence), dropped out due to adverse events (RR 0.33, 95% CI 0.13 to 0.82; P = 0.017; lowâcertainty evidence), or experienced at least one severe adverse event (RR 0.91, 95% CI 0.64 to 1.28; P = 0.58; lowâcertainty evidence) during the trial.
One RCT compared inotersen with placebo (172 randomised participants). The trial did not explore our predetermined disability outcome measures. From baseline to week 66, inotersen reduced progression of peripheral neuropathy more than placebo (modified NIS plus 7 nerve tests â Ionis version; MD â19.73 points, 95% CI â26.50 to â12.96; P < 0.001; moderateâcertainty evidence). At week 65, the change in quality of life between groups favoured inotersen (Norfolk QOLâDN total score; MD â10.85 points, 95% CI â17.25 to â4.45; P < 0.001; lowâcertainty evidence). Inotersen may slightly increase mortality (RR 5.94, 95% CI 0.33 to 105.60; P = 0.22; lowâcertainty evidence) and occurrence of severe adverse events (RR 1.48, 95% CI 0.85 to 2.57; P = 0.16; lowâcertainty evidence) compared to placebo. More dropouts due to adverse events were observed in the inotersen than in the placebo group (RR 8.57, 95% CI 1.16 to 63.07; P = 0.035; lowâcertainty evidence).
There were no studies addressing apolipoprotein AIâFAP, gelsolinâFAP, and betaâ2âmicroglobulinâFAP.
Authors' conclusions
Evidence on the pharmacological treatment of FAPs from RCTs is limited to TTRâFAP. No studies directly compare diseaseâmodifying pharmacological treatments for TTRâFAP. Results from placeboâcontrolled trials indicate that tafamidis, diflunisal, patisiran, and inotersen may be beneficial in TTRâFAP, but further investigations are needed. Since direct comparative studies for TTRâFAP will be hampered by sample size and costs required to demonstrate superiority of one drug over another, longâterm nonârandomised openâlabel studies monitoring their efficacy and safety are needed
Ulteriori dati sulla distribuzione in Toscana di Ropaloceri poco noti o di interesse conservazionistico (Insecta: Lepidoptera: Papilionidae, Riodinidae, Lycaenidae, Nymphalidae)
New records are reported of Zerynthia cassandra (Geyer, 1828), Hamearis lucina (Linnaeus, 1758), Thecla betulae (Linnaeus, 1758), Phengaris arion (Linnaeus, 1758), Lysandra hispana (HerrichSchĂ€ffer, 1851), Brenthis hecate ([Denis & SchiffermĂŒller], 1775), Boloria dia (Linnaeus, 1767), Apatura ilia ([Denis & SchiffermĂŒller], 1775), Libythea celtis (Laicharting, [1782]), Danaus chrysippus (Linnaeus, 1758) and Melanargia arge (Sulzer, 1776), Ropalocerans uncommon or of conservation interest in Tuscany. These records contribute to the Tuscan distribution of these species and in some cases are the first reports for the Special Areas of Conservation (SAC) established pursuant to Directive 92/43 / EEC
Integrating computational methods to predict mutagenicity of aromatic azo compounds
Azo dyes have several industrial uses. However, these azo dyes and their degradation products showed mutagenicity, inducing damage in environmental and human systems. Computational methods are proposed as cheap and rapid alternatives to predict the toxicity of azo dyes. A benchmark dataset of Ames data for 354 azo dyes was employed to develop three classification strategies using knowledge-based methods and docking simulations. Results were compared and integrated with three models from the literature, developing a series of consensus strategies. The good results confirm the usefulness of in silico methods as a support for experimental methods to predict the mutagenicity of azo compounds
- âŠ